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Introduction
Autoinflammatory diseases (AIDs) represent a group of
monogenic disorders, related to mutations in genes encod-
ing proteins involved in the regulation of inflammatory
responses. The aims of therapy in AIDs patients are con-
trolling disease activity, improving patient’s quality of life
and preventing long-term complications. Biological agents
have recently changed the natural history and the prog-
nosis of AIDs. According to a pathogenetic criterium, they
can be classified as:
1 ) Anti-TNF agents: i) Etanercept, a dimeric fusion
protein of TNFR2 linked with the Fc region of human
IgG1, ii) Adalimumab, a fully human monoclonal anti-
TNF antibody, iii) Infliximab, a mouse/human chimeric
monoclonal anti-TNF antibody [1,2].
2) Anti-IL-1 agents: i) Anakinra, a competitive IL-1
receptor antagonist, ii) Canakinumab, a fully humanized
anti-IL-1 monoclonal antibody, iii) Rilonacept, a fusion
protein of IL-1 extracellular domains and Fc region of
human IgG [1].
3) Anti-IL-6 agents: Tocilizumab, a monoclonal anti-
body binding and inhibiting both soluble and membrane
IL-6 receptor [1,2].
Clinical use of biological drugs in
autoinflammatory disorders
® Familiar Mediterranean Fever (FMF) is the only
autoinflammatory disease in which a “classical” immuno-
modulator (colchicine) still plays a central role [3]. None-
theless, a relevant number of non complete responders
has been recently observed. According to the pivotal role
of IL-1 in the pathogenesis of FMF [4,5], anti-IL-1 treat-
ment has been employed in colchicine-resistant patients,
with good response in terms of control of disease activity
and systemic impairment [6,7].
® In TRAPS (TNF Receptor Associated Periodic Fever
Syndrome) patients, the failure of Infliximab and Adalimu-
mab in controlling inflammatory flares has been already
described [8]. Etanercept does not completely normalize
symptoms or acute phase reactants [9] and the progressive
development of neutralizing antibodies may compromise
its effectiveness [2]. On the other hand, recent papers have
shown the dramatic and persistent efficacy of anti-IL-1
treatment in TRAPS patients [10,11].
® In CAPS (Cryopirin Associated Periodic Syndromes)
patients treated with Anakinra, the clinical improvement
appears to be strictly dependent on continuous drug
administration [12,13]. Moreover, preliminary results on
Rilonacept and Canakinumab seem to be promising
[14-16].
® In Hyper-IgD (Mevalonate Kinase Deficiency), Ana-
kinra has shown to be markedly effective in different case
reports, while Etanercept provided variable results [2].
Conclusions
Although biologic agents are related to frequent side
effects, their administration has revolutionized the clini-
cal approach to AIDs patients. Further trials are needed
to definitively assess their safety and efficacy.
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